Pharma Exporters Facing Issues with Online National Drug Licensing System

Why It Matters

Delays in COPP issuance can disrupt export schedules, eroding India’s competitive edge in the global pharma market and risking contractual penalties for exporters.

Key Takeaways

• Exporters report technical glitches on ONDLS portal
• COPP processing delays threaten shipment timelines
• Pharmexcil to lobby CDSCO for system fixes
• WHO GMP compliance adds regulatory complexity
• CDAC and CDSCO jointly manage licensing platform

Pulse Analysis

The Online National Drug Licensing System (ONDLS) was introduced to streamline the issuance of Certificates of Pharmaceutical Products (COPP), a prerequisite for Indian drug manufacturers to access overseas markets under the World Health Organization’s Good Manufacturing Practices (GMP) framework. By digitizing applications, the platform aims to reduce paperwork, accelerate approvals, and provide a single‑window interface for exporters, regulators, and health authorities. In theory, ONDLS should enhance transparency and align India’s export processes with international standards, bolstering the country’s reputation as a reliable pharma supplier.

Since its rollout, several exporters have flagged persistent technical glitches, ranging from login failures to incomplete data validation, which stall the submission of COPP applications. These bottlenecks have translated into processing delays that jeopardize shipment schedules, especially for time‑sensitive products such as vaccines and biologics. Moreover, the new WHO GMP requirements embedded in the system add a layer of regulatory complexity, forcing firms to adapt quickly or risk non‑compliance. The cumulative effect is a heightened risk of missed delivery windows, potential penalties, and strained relationships with foreign buyers.

Recognizing the stakes, the Pharmaceuticals Export Promotion Council (Pharmexcil) is acting as an industry advocate, gathering detailed feedback and presenting it to the Central Drugs Standard Control Organisation (CDSCO). By channeling exporter concerns, Pharmexcil seeks expedited fixes, clearer guidance on GMP compliance, and a more resilient ONDLS infrastructure. A swift resolution will safeguard India’s export pipeline, preserve market share in competitive therapeutic segments, and reinforce confidence among global partners that Indian pharma can reliably meet stringent quality and timing expectations.